 Prednisone
"Prednisone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
| Descriptor ID |
D011241
|
| MeSH Number(s) |
D04.808.745.432.719.702
|
| Concept/Terms |
Prednisone- Prednisone
- Dehydrocortisone
- delta-Cortisone
Winpred- Winpred
- ICN Brand of Prednisone
Cortancyl- Cortancyl
- Panafcort
- Aventis Brand of Prednisone
Cutason- Cutason
- mibe Brand of Prednisone
Dacortin- Dacortin
- Merck Brand of Prednisone
- Decortin Brand of Prednisone
Deltasone- Deltasone
- Pharmacia Brand of Prednisone
Meticorten- Meticorten
- Schering-Plough Brand of Prednisone
Orasone- Orasone
- Solvay Brand of Prednisone
Panasol- Panasol
- Seatrace Brand of Prednisone
Rectodelt- Rectodelt
- Trommsdorff Brand of Prednisone
Sone- Sone
- Fawns & McAllan Brand of Prednisone
Cortan- Cortan
- Halsey Drug Brand of Prednisone
|
Below are MeSH descriptors whose meaning is more general than "Prednisone".
Below are MeSH descriptors whose meaning is more specific than "Prednisone".
This graph shows the total number of publications written about "Prednisone" by people in this website by year, and whether "Prednisone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 2 | 2 | | 1981 | 0 | 1 | 1 | | 1982 | 0 | 7 | 7 | | 1984 | 1 | 2 | 3 | | 1986 | 0 | 1 | 1 | | 1987 | 2 | 5 | 7 | | 1988 | 1 | 4 | 5 | | 1989 | 2 | 5 | 7 | | 1990 | 1 | 4 | 5 | | 1991 | 2 | 3 | 5 | | 1992 | 0 | 5 | 5 | | 1993 | 2 | 4 | 6 | | 1995 | 2 | 5 | 7 | | 1996 | 2 | 8 | 10 | | 1997 | 0 | 8 | 8 | | 1998 | 4 | 7 | 11 | | 1999 | 3 | 2 | 5 | | 2000 | 0 | 2 | 2 | | 2001 | 4 | 1 | 5 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 3 | 4 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 5 | 5 | | 2007 | 1 | 2 | 3 | | 2008 | 0 | 4 | 4 | | 2009 | 2 | 6 | 8 | | 2010 | 1 | 9 | 10 | | 2011 | 0 | 2 | 2 | | 2012 | 2 | 3 | 5 | | 2013 | 0 | 1 | 1 | | 2014 | 2 | 5 | 7 | | 2015 | 2 | 2 | 4 | | 2016 | 0 | 5 | 5 | | 2017 | 3 | 4 | 7 | | 2018 | 0 | 5 | 5 | | 2019 | 3 | 2 | 5 | | 2020 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Prednisone" by people in Profiles.
-
Bhatia SM, Streilein RD, Hall RP. Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab. PLoS One. 2020; 15(6):e0233957.
-
Yuen C, Soliven B, Rezania K. ATM mutation in a patient with thymoma-associated myasthenia gravis. Muscle Nerve. 2020 08; 62(2):E50-E52.
-
Chow M, Kamath S, Choi D, Kim G, Ahronowitz I. Violaceous Plaques and Nodules: Answer. Am J Dermatopathol. 2020 Jan; 42(1):63-64.
-
Chow M, Kamath S, Choi D, Kim G, Ahronowitz I. Violaceous Plaques and Nodules: Challenge. Am J Dermatopathol. 2020 Jan; 42(1):e3.
-
Quattrocelli M, Zelikovich AS, Jiang Z, Peek CB, Demonbreun AR, Kuntz NL, Barish GD, Haldar SM, Bass J, McNally EM. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight. 2019 12 19; 4(24).
-
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141.
-
George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 11; 79(15):1752-1761.
-
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 07 20; 37(21):1790-1799.
-
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
-
Agarwal A, Hall RP, Bañez LL, Cardones AR. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. PLoS One. 2018; 13(9):e0198074.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|